J&J’s subsidiary Codman Neuro buys Irish’s Neuravi Limited

Johnson & Johnson’s company Codman Neuro has acquired Neuravi Limited, a company dedicated to advancing neurovascular therapies and improving clinical outcomes for acute ischemic stroke patients.

Neuravi is privately held Irish company founded in 2009. The company has invested in scientific research on the varieties of clots that cause acute ischemic stroke, and has translated learnings into its EmboTrap Revascularization Platform.

Stroke is the second global leading cause of death after the age of 60, and ischemic strokes, caused by blockages in vessels supplying blood to the brain, account for 87% of all strokes, the Johnson said in its press release.

“Rapid restoration of flow is of utmost importance when treating stroke patients,” said Shlomi Nachman, Company Group Chairman of Johnson & Johnson Medical Devices Cardiovascular & Specialty Solutions. “The EmboTrap platform was designed to address this critical need and we are excited to combine Neuravi’s expertise in clot research with Codman Neuro’s global resources to accelerate innovation in acute ischemic stroke treatment.”